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Abstract
Background: Human polyomavirus JC (JCV) is the etiologic agent of a brain disease, known as progressive
multifocal leukoencephalopathy (PML). The JCV genome encodes a small multifunctional phospho-protein,
agnoprotein, from the late coding region of the virus, whose regulatory functions in viral replication cycle remain
elusive. In this work, the functional role of JCV and SV40 agnoproteins in virion release was investigated using a
point mutant (Pt) of each virus, where the ATG codon of agnoprotein was mutated to abrogate its expression.
Results: Analysis of both viral protein expression and replication using Pt mutant of each virus revealed that both
processes were substantially down-regulated in the absence of agnoprotein compared to wild-type (WT) virus.
Complementation studies in cells, which are constitutively expressing JCV agnoprotein and transfected with the
JCV Pt mutant genome, showed an elevation in the level of viral DNA replication near to that observed for WT.
Constitutive expression of large T antigen was found to be not sufficient to compensate the loss of agnoprotein
for efficient replication of neither JCV nor SV40 in vivo. Examination of the viral release process for both JCV and
SV40 Pt mutants showed that viral particles are efficiently released from the infected cells in the absence of
agnoprotein but were found to be mostly deficient in viral DNA content.
Conclusions: The results of this study provide evidence that agnoprotein plays an important role in the
polyomavirus JC and SV40 life cycle. Infection by agnoprotein-negative mutants of both viruses results in the
release of virions that are mostly deficient in DNA content.
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Background
A large number of studies indicate that the small regula-
tory proteins of many viruses play important roles in
various aspects of viral infection cycle, including replica-
tion [1-3], transcription [4-10], translation [11], export
of viral transcripts from nucleus to cytoplasm [12], viral
assembly [13] and release of viral particles [14,15]. In
addition, these proteins may also modulate host-cell
functions by deregulating the expression of key cellular
genes [16]. Therefore, such regulatory proteins are
important for successful completion of the viral life
cycle and study of their regulatory roles in viral life
cycle is critically important for understanding of the
viral replication process and the disease progression that
respective viruses induce in their host.
The late coding region of human polyomavirus JC
(JCV) and simian virus 40 (SV40) encodes a small regu-
latory phosphoprotein, agnoprotein, whose expression
during the viral lytic cycle has been demonstrated by
biochemical and immunocytochemical methods [17-19].
Agnoprotein is a cytoplasmic protein predominantly
localized to the perinuclear region of infected cells. A
small amount of agnoprotein is also detected in nucleus
in the infected cells. The expression pattern of agnopro-
tein in tissue sections from progressive multifocal leu-
koencephalopathy (PML) has also been analyzed and
also shown to localize to the cytoplasmic and perinuc-
lear regions of the infected brain cells from PML
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agnoproteins for JCV, BKV and SV40 shows a high
degree of sequence identity of about 70% [10,21]. While
the amino-terminal and central regions of each agnopro-
tein exhibit considerable sequence identity with one
another, sequences toward the carboxy-terminal region
are more divergent.
JCV is the etiologic agent of the fatal demyelinating
disease of the brain, PML [7,22-25] and its late gene
product, agnoprotein, has been previously shown to
functionally interact with other JCV regulatory proteins,
including large T-antigen [10] and small t-antigen [26]
and several cellular factors [16,19]. In addition, agnopro-
tein has been shown to have inhibitory effects on cell
cycle progression [16]. Mutational analysis of agnopro-
tein from the closely related virus SV40 suggested that
it may have effects on various aspects of the viral lytic
cycle including transcription, translation, virion produc-
tion and maturation of the viral particles [27-34]. It has
been known for more than a decade that SV40 and
BKV agnoproteins are phosphorylated but no function
has yet been assigned to this modification [18,35]. More
recent studies explored the possibility that potential
phosphorylation sites of agnoprotein are the targets for
well-characterized protein kinases, including protein
kinase C (PKC). Indeed, these studies demonstrated that
agnoprotein is phosphorylated by PKC and phosphoryla-
tion turns out to play a significant role in the function
of this protein during the viral replication cycle [36,37].
More recent reports also showed that agnoprotein dele-
tion mutants are non-functional but can be rescued by
trans-complementation [36,38]. In addition, it has been
suggested that agnoprotein aids in the release of virions
from infected cells [39].
In order to delineate whether agnoprotein is involved
in release of viral particles from infected cells, we have
utilized point mutants of JCV and SV40 agnoproteins in
which the ATG translation initiation codon of agnogene
was altered and thereby the expression of the protein
was ablated. In this report, we provide experimental evi-
dence indicating that both JCV and SV40 virions are
efficiently released from the infected cells in the absence
of agnoprotein, however, the released viral particles are
mostly deficient in DNA content, which greatly hampers
the ability of the propagation of the mutant virus rela-
tive to wild-type.
Methods
Cell lines
Primary human fetal glial (PHFG) cells were prepared as
follows: Brain tissue from an aborted 16-week-old fetus
was first cut into small pieces in Hanks balanced salt
solution (HBSS) and the clumps were mechanically dis-
rupted by repeated pipetting of the soft tissue. To further
separate the cells, the tissue was incubated at 37°C with
trypsin (0.005%) and DNAse I (50 μg/ml) for 30 min.
Fetal bovine serum (0.1%) was then added to inactivate
trypsin and the cells were washed with HBSS twice to
remove trypsin. The cells were then passed through a 70
mm mesh to remove larger cell clumps. The cells in the
filtrate were spun down and the pellet was resuspended
in a small volume of HBSS with a fire polished glass pip-
ette to obtain single cells. After cell viability and count
were determined, cells were resuspended in growth
media D-MEM+F12 containing fetal bovine serum, FBS
(10%), L-glutamine (2 mM), insulin (2.5 mg/l) and genta-
mycin (50 mg/l). The cells were plated on collagen-
coated flasks at a concentration of 2-10 × 10
6 per 75 cm
2
flask and incubated at 37°C. SVG-A is a subclonal popu-
lation of a human glial cell line which was established by
transformation of human fetal glial cell line with an ori-
gin-defective SV40 mutant [40]. SVG-A cells were grown
in Dulbecco’sM o d i f i e dE a g l e ’s Medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS) and antibiotics (penicillin/streptomycin, 100 μg/ml).
They were maintained at 37°C in a humidified atmo-
sphere with 7% CO2. Cos-7 cells were grown in Dulbec-
co’s Modified Eagle’s Medium (DMEM) supplemented
with 10% (FBS) and antibiotics (penicillin/streptomycin,
100 μg/ml). They were maintained at 37°C in a humidi-
fied atmosphere with 7% CO2.
Stable cell lines
SVG-A cells (2 × 10
5 cells/100 mm tissue culture dish)
were either stably transfected with pcDNA3-JCV agno-
protein expression plasmid (pcDNA3-JCV-Agno) (5 μg/
plate) [10] or pcDNA3 vector alone (Invitrogen) (5 μg/
plate) by lipofectin method according to manufacturer’s
recommendations (Invitrogen). At five hour posttrans-
fection, transfectants were washed twice with phosphate
buffered saline (PBS) and refed with DMEM containing
10% FBS. After twenty-four hours, cells from each 100-
mm plate were trysinized and replated onto ten 100-
mm plates. Cells were allowed to attach for six hours
and then the medium was replaced with DMEM con-
taining 400 μg/ml G418 and 10% FBS. The medium was
changed every three days until individual colonies
formed. Individual colonies were randomly selected,
screened for agnoprotein expression by Western blot-
ting, expanded and frozen in liquid nitrogen.
Plasmid constructs
Description of both JCV WT (Bluescript KS+JCV-Mad-1
W T )a n dJ C Va g n o p r o t e i np o i n tm u t a n t( B l u e s c r i p t
KS+JCV-Mad-1 Pt) was previously described [36].
Simian virus 40 genome [SV40(776)] was subcloned
from pBR322 vector into Bluescript KS+ at the BamH
I site and designated as Bluescript KS+SV40(776) WT.
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an “Excite™ PCR-based site-directed mutagenesis Kit”
(Stratagene) utilizing the following primers: Primer 1.
SV40(776) (331-362): 5’-GG AGA TCT TGC TGC GCC
GGC TGT CAC GCC AGG-3’. Primer 2. SV40(776)
(330-309): 5’-TGA AAT AAC CTC TGA AAG AGG-3’.
Underlined sequence represents the substitution of Nco
I site with a newly created Bgl II site. PCR was per-
formed according to manufacturer’s recommendations.
Briefly, 10 ngs of Bluescript KS+SV40(776) WT plasmid
were PCR amplified with 15 picomols of each primer
shown above under stringent reaction conditions. Pri-
mers were phosphorylated by T4 polynucleotide kinase
at 5’-ends before PCR reaction. After initial denaturation
of the plasmid for 10 min at 94°C, reaction was cycled
12 times under the following parameters: 95°C, 2 min;
56°C, 2 min; and 72°C 8 min; and 72°C 10 min for one
cycle. Upon PCR reaction, the PCR product was treated
with Dpn I enzyme to eliminate template DNA, reli-
gated and transformed into supercompetent Epicurian
Coli XL-1-Blue supercompetent cells (Stratagene). In the
point mutant construct, Nco I site (CCATGG) of WT
strain containing the translation initiation codon (ATG)
of agnoprotein was converted into Bgl II site (AGATCT)
by base substitution which allowed us to distinguish the
mutant from WT by restriction enzyme digestion.
Finally, base substitutions and overall integrity of the
viral DNA sequences were verified by DNA sequencing
f o rS V 4 0P ta n dJ C VP tp l a s m i d s .p c D N A 3-JCV-Agno-
protein expression plasmid (pcDNA3-JCV-Agno) was
described previously [10].
Transfections
Both PHFG and SVG-A cells (2 × 10
6 cell/75 cm
2 flask)
were transfected either with Mad-1 WT (8 μg) or Mad-
1P t( 8μg) mutant JCV viral DNA using lipofectin-2000
according to manufacturer’s recommendations (Invitro-
gen). CV-1 cells (1.5 × 10
6 cell/75 cm
2 flask) were trans-
fected either with SV40(776) WT (8 μg) or SV40(776) Pt
(8 μg) mutant viral DNA using lipofectin-2000. At five
hour posttransfection, cells were washed twice with PBS.
Cos-7 cells were transfected as described for CV-1 cell
lines. PHFG cells were fed with D-MEM+F12 containing
FBS (10%), L-glutamine (2 mM), insulin (2.5 mg/l) and
gentamycin (50 mg/l); and SVG-A, Cos-7 and CV-1
cells were fed with DMEM supplemented with 5% FBS.
Western blotting
Whole-cell extracts prepared from PHFG cells untrans-
fected or transfected with either WT JCV Mad-1 gen-
o m eo rJ C VM a d - 1P tm u t a n tg e n o m ea t7 d ,1 4 d ,a n d
21d posttransfection were resolved on SDS-15% PAGE
and blotted onto nitrocellulose membranes. Blotted
membranes were probed with an anti-agnoprotein
polyclonal antibody as described previously [19] and
detected by a chemiluminescence (ECL) method accord-
ing to the manufacturer’s recommendations (Amer-
sham). In parallel, nuclear extracts prepared from either
transfected or untransfected cells were analyzed for viral
VP1 and large T antigen (LT-Ag) by Western blotting
utilizing a monoclonal anti-VP1 antibody (PAb 597)
(a kind gift from Dr. W. Atwood, Brown University,
Rhode Island) and a monoclonal anti-SV40 LT-Ag anti-
body (Ab-2), which is cross-reactive with JCV LT-Ag
respectively. Similarly, whole-cell and nuclear extracts
prepared from SVG-A cells stably expressing JCV agno-
protein which were either transfected with JCV Mad-1
WT or JCV Mad-1 Pt mutant were analyzed for agno-
protein. In addition, whole-cell and nuclear extracts
were prepared from CV-1 cells untransfected or trans-
fected with either SV40(776) WT genome or SV40(776)
Pt mutant genome at indicated time points posttransfec-
tion. Extracts were then analyzed for SV40 agnoprotein,
LT-Ag and VP1 expression by Western blotting using
anti JCV agnoprotein, anti-SV40 LT-Ag (Ab-2) and
anti-JCV VP1 (PAb597) antibodies. Western blots were
probed with an anti-lamin A antibody to demonstrate
the equal loading of the protein extracts.
Replication assay
Replication assays were carried out as previously
described [10]. Briefly, PHFG cells or SVG-A cells (2 ×
10
6 cells) grown in 75 cm
2 flasks were transfected either
with JCV Mad-1 WT or JCV Mad-1 Pt mutant viral
genome (8 μg/2 × 10
6 cells/75 cm
2 flask) by lipofectin-
2000 transfection method. Of note, The pBluescript
(back bone) vector from both JCV and SV40 plasmids
was digested with BamH I before using the plasmids in
transfections. Lipofectin-DNA mixture was incubated
with cells for 5 h and washed with PBS. Transfected
SVG-A cells were fed with complete D-MEM media
with 3% FBS. Transfected PHFG cells were fed with a
special growth media D-MEM+F12 media containing
10% FBS, L-Glutamine (2 mM), gentamycin (50 mg/l)
and insulin (2.5 mg/l). At indicated time points post-
transfection, low-molecular-weight DNA containing
both input and replicated viral DNA was isolated by the
Hirt method [41], digested with BamHIa n dDpn
I enzymes, resolved on a 1% agarose gel and analyzed by
Southern blotting.
Indirect immunofluorescence microscopy
Indirect immunofluorescence microscopy studies were
performed as previously described [19,42,43]. Briefly,
CV-1 cells transfected with either SV40(776) WT or its
Pt mutant genome were seeded at subconfluency on
polylysine-coated glass chamber slides at 5
th day post-
transfection. The next day, cells were washed twice with
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with 5% bovine serum albumin in PBS for 2 h and incu-
bated with a monoclonal primary anti-SV40 large
T antigen (Ab-2) antibody overnight. Cells were subse-
quently washed four times with PBS-0.01% Tween 20
for 10-min intervals and incubated with an anti-mouse
fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse secondary antibody for 45 min. Finally, the slides
were washed three times with PBS, mounted, and exam-
ined under fluorescence microscope for detection of
LT-Ag. Indirect immunofluorescence microscopy studies
were performed for JCV Mad-1 WT and its Pt mutant.
SVG-A cells transfected with either JCV Mad-1 WT or
its Pt mutant genome were seeded at subconfluency on
polylysine-coated glass chamber slides at 6
th day post-
transfection and processed for detection of agnoprotein
and VP1 as described above for SV40 using anti-Agno
polyclonal [19] and anti-VP1 monoclonal (PAb597) pri-
mary antibodies followed by incubation with a FITC-
conjugated goat anti-rabbit and Rhodamine-conjugated
goat anti-mouse secondary antibodies respectively as
described in each figure legend. Indirect immunofluores-
cence microscopy studies were also performed for SV40
(776) WT and its Pt mutant in Cos-7 cells as described
in the respective figure legend.
Viral particle release assay
Mad-1 WT genome or its agnoprotein Pt mutant were
separately transfected into SVG-A cells (8 μgD N A / 2×
10
6 cells/75 cm
2 flask). Supernatants from infected cells
were collected at indicated time points, centrifuged at
16,000×g to clear cell debris and were subjected to
immunoprecipitation using an anti-VP1 antibody
(PAb597) (2 μg ) .H a l fo ft h es a m p l e sw e r ea n a l y z e db y
Western blotting using anti-VP1 antibody (PAb597), the
other half was analyzed by Southern blotting for detec-
tion of encapsidated viral DNA. The viral DNA from
capsids was purified employing Qiagen spin columns
[44], digested with BamH I and Dpn I enzymes, resolved
on an 1% agarose gel and analyzed by Southern blotting
using probes prepared from whole Mad-1 genome. In
parallel, SV40(776) WT or its Pt mutant DNA was
transfected into CV-1 cells (8 μg/2 × 10
6 cells/75 cm
2
flask) and supernatants of the samples were collected at
indicated time points and processed as described above
for JCV Mad-1 WT and its Pt mutant.
Results
Both viral early and late protein expression are markedly
reduced in the absence of agnoprotein
JCV agnoprotein is a small basic phospho-protein and
little is known about its regulatory roles in viral replica-
tion cycle. In this study, we investigated whether indeed
JCV and SV40 agnoproteins play regulatory roles in
release of virions from infected cells, utilizing agnopro-
tein point mutants of each virus. We first sought to
determine whether JCV agnoprotein plays a role in reg-
ulation of the viral early gene expression by introducing
JCV Mad-1 WT and its Pt mutant genomes into PHFG
by transfection and analyzing the protein expression by
Western blotting. At 7d, 14d and 21d after transfection,
nuclear extracts were prepared and analyzed to deter-
mine the level of LT-Ag expression by immunoblotting.
Of note, the virus infection cycle initiates upon transfec-
tion of the viral genome into the permissive cells. As
shown in Figure 1A, the level of LT-Ag expression from
the WT early promoter gradually increased as the JCV
infection cycle reached 21d posttransfection (lanes 4-6).
In contrast, the level of expression of LT-Ag was almost
undetectable in nuclear extracts prepared from the cells
transfected with its Pt mutant genome at days 7 and 14
(lanes 1 and 2), and barely detectable for 21d posttran-
fection (lane 3). Comparison of the band intensities
corresponding to LT-Ag for WT versus Pt mutant gen-
omes at 21d posttransfection by densitometry showed
that JCV early gene expression was reduced ~25 fold in
the absence of agnoprotein (lanes 3 and 6 respectively).
In parallel, absence and presence of the agnoprotein
expression in whole-cell extracts was analyzed by immu-
noblotting from the JCV Pt mutant and the WT back-
grounds (Figure 1A bottom panel). While expression of
agnoprotein from the WT background was readily
detectable (lanes 4-6), as expected, its expression was
absent from the Pt background (lanes 1-3).
In the case of SV40, we also assessed the effect of
agnoprotein on viral early gene expression using its Pt
mutant genome. CV-1 cells, which are permissive for
SV40 replication, were transfected with either SV40(776)
WT or its Pt mutant genome. Nuclear extracts were
prepared at the time points indicated and analyzed by
Western blotting for the expression of SV40 LT-Ag. As
shown in Figure 1B, expression of LT-Ag from both
WT and the mutant backgrounds 24h (1d) after trans-
fection (upper panel, lane 2) was readily detectable but
the level of SV40 LT-Ag expression in cells transfected
with the Pt mutant genome decreased significantly
(compare lane 3 with 2). A similar expression profile
was observed for both mutant and WT viruses even at
3d after transfection. Interestingly, at 6d and 9d after
transfection, whereas the level of LT-Ag expression
from WT background gradually but substantially
increased (lanes 6 and 8), that of LT-Ag from the Pt
mutant background reduced to barely detectable levels
(lanes 7 and 9). In parallel, we analyzed the presence
and absence of agnoprotein expression in whole cell
extracts from SV40 WT and SV40 Pt mutant back-
grounds respectively (Figure 1B, bottom panel). While
t h ee x p r e s s i o no fS V 4 0a g n o p r o t e i nw a sr e a d i l y
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Figure 1 Analysis of the expression levels of LT-Ag from JCV Pt and SV40 Pt backgrounds. (A) PHFG cells were transfected/infected either
with JCV Mad-1 WT or its Pt mutant genome, nuclear and whole-cell extracts prepared at the indicated time points and analyzed by Western
blot for LT-Ag and agnoprotein respectively. Lamin A/C was also probed for equal loading of the nuclear extracts for LT-Ag using anti-lamin A/C
polyclonal antibody (Cat #: 2032, Cell signaling). Western blotting with anti-Grb2 monoclonal antibody (Santa Cruz, C-7, Cat #: sc-8034)
demonstrates the equal loading of the samples for agnoprotein expression (bottom panel). (B) CV-1 cells were transfected either with SV40(776)
WT or its Pt mutant genome, the whole-cell and nuclear extracts prepared at the days indicated and analyzed by Western blot for agnoprotein
and LT-Ag expression. An unlabeled arrow points to the band that is recognized by anti-Agno antibody which serves as a loading control for
the agnoprotein samples. In lane 1, nuclear extracts prepared from untransfected cells were loaded as negative control (- Cont.).
Sariyer et al. Virology Journal 2011, 8:255
http://www.virologyj.com/content/8/1/255
Page 5 of 15detectable in CV-1 cells transfected with WT genome
(lanes 4, 6 and 8), as expected, its expression was not
evident in cells transfected with SV40 Pt mutant gen-
ome (lanes 3, 5, 7 and 9).
We next analyzed the level of SV40 early gene expres-
sion in the absence of agnoprotein by immunocyto-
chemistry for LT-Ag. CV-1 cells were transfected with
either WT or Pt SV40 mutant genome, fixed at 4d after
transfection, incubated with a monoclonal antibody to
SV40 LT-Ag (Ab-2) and then incubated with a FITC-
conjugated secondary antibody. Examination of the cells
under a fluorescence microscope for LT-Ag expression
showed that SV40 WT infected close to 100% of the
cells by day 4, (i.e., nearly all cells were immunocyto-
chemically positive for LT-Ag) (Figure 2, upper panels).
In contrast, SV40 Pt mutant was able to infect less than
1-5% of the cell population as assessed by detection of
LT-Ag at day 4 after transfection (Figure 2, lower
panels).
As analyzed for the expression level of SV40 early
genes (Figure 2), we also analyzed the level of VP1
expression for JCV Mad-1 strain and its Pt mutant in
the absence of agnoprotein in SVG-A cells by immuno-
cytochemistry (Figure 3). Transfected/infected cells were
fixed at 6
th day posttransfection and analyzed for the
late capsid gene expression, VP1, as described in the fig-
ure legend. Since JCV is a slow growing virus compared
to SV40 in tissue culture, a small number of cells were
found to be positive for both JCV WT and its Pt
mutant. However, our data showed that the number of
positive cells for VP1 expression for Pt were always less
than that of WT, which is consistent with our findings
for the SV40 Pt mutant (Figure 2).
We also compared the viral late gene expression from
WT versus Pt backgrounds by Western blotting for
VP1. Nuclear extracts were prepared at 7d, 14d and 21d
after transfection of PHFG cells with JCV Mad-1 WT or
Pt mutant and analyzed by Western blot using a mono-
clonal anti-JCV VP1 antibody. As shown in Figure 4A,
although there was a gradual increase in the level of
VP1 expression from both WT and the mutant back-
grounds as the infection cycle progressed over the 21
day time course, we observed a significant reduction in
the level of VP1 expression from the mutant compared
to WT (compare lanes 4 and 7).
The effect of SV40(776) Pt mutant on viral late gene
expression was also analyzed. Nuclear extracts prepared
from CV-1 cells transfected with either SV40(776) WT
or the Pt mutant genome were analyzed by Western
blot for VP1. As shown in Figure 4B, the level of SV40
VP1 expression, although demonstrated a relatively low
but steady expression for 1 and 3 days after transfection
(lanes 2-5) followed by a very strong increase at 6 and 9
days for WT (lanes 6 and 8 respectively). In contrast, Pt
mutant showed a declining course after 3 days where
the level of VP1 expression dropped to undetectable
levels at 6 days and 9 days (lanes 7 and 9 respectively)
similar to the pattern of early gene expression described
above (Figure 1B, upper panel). Collectively, all these
results suggest that, in the absence of agnoprotein, JCV
and SV40 protein expression (early and late) appear to
be severely down-regulated.
Replication efficiency of JCV and SV40 greatly diminished
in the absence of agnoprotein
Since viral early and late gene expression is negatively
affected in the absence of agnoprotein (Figure 1 and 4),
we next assessed the functional consequences of this
effect on viral DNA replication by employing a Dpn
I replication assay. JCV Mad-1 WT or the Pt mutant
genome was transfected into SVG-A cells and at 7d, 14d
and 21d posttransfection, low-molecular weight DNA
was isolated by the Hirt method [41]. Subsequently,
newly replicated Dpn I-resistant DNA was analyzed by
Southern blotting. It was observed that the replication
efficiency of the JCV Mad-1 Pt mutant was much lower
than WT (Figure 5A), even though SVGA cells constitu-
tively express SV40 LT-Ag, which has been shown to
cross-regulate JCV DNA replication [45-49]. For example,
at day 14 after transfection, the level of DNA replication
for Pt mutant was about 4.3-fold less than that of the
WT (compare lane 4 to 5). At day 21 posttransfection,
SV40 WT
SV40 Agno
Pt Mutant
FITC PHASE
Figure 2 Immunocytochemical analysis of CV-1 cells,
transfected/infected either with SV40(776) WT or the Pt
mutant genome, for detection of LT-Ag expression. CV-1 cells
were transfected either with SV40(776) WT or the Pt mutant
genome, fixed at 4
th day posttransfection, incubated with a primary
anti-SV40 LT-Ag (Ab-2) antibody followed by incubation with a FITC-
conjugated goat anti-mouse secondary antibody and examined
under a fluorescence microscope for detection of SV40 LT-Ag
expression.
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became even more pronounced (~19-fold, compare lane
6 to 7). These results are consistent with our previous
findings, where we showed that replication of JCV Pt
mutant was significantly hampered in the absence of
agnoprotein [36]. Of note, the origin of JCV DNA repli-
cation and auxiliary DNA sequences necessary for the
efficient replication of the Pt mutant remained intact
after manipulations of the viral genome during the muta-
genesis process, which is evident from the DNA sequen-
c i n gd a t a .A l s on o t et h a tS V G - Ac e l l sd on o te x p r e s s
either SV40 VP1 or SV40 agnoprotein [19] but constitu-
tively express LT-Ag. The above findings suggest that
providing LT-Ag in trans is not sufficient to bring the
levels of JCV viral replication to that of WT in the
absence of agnoprotein. In addition to SVG-A cells, we
also used PHFG cells in replication assays and obtained
consistent results as obtained for SVG-A cells (see addi-
tional file 1 figure S1, compare lane 6 with 7).
We next examined the replication properties of the
SV40 Pt mutant compared to WT in CV-1 monkey kid-
ney cells to see if it behaves in a similar manner
observed for JCV. The results from this replication stu-
dies showed that the replication efficiency of the SV40
Pt mutant was also hampered compared to the WT
(Figure 5B). The level of replicated DNA from WT virus
gradually increased during the course of the infection
cycle until 9th day posttransfection. However, the
amount of replicated DNA for SV40 Pt mutant virus
declined after 3th days following transfection reaching a
point where its replication was barely detectable after
day 6 of the infection cycle, which is consistent with the
results obtained from viral protein expression studies in
Figure 1B. The quantitative analysis of the results
showed that there was approximately 120-fold more
replicated DNA for the WT compared to the mutant at
day 9 posttransfection.
Stable expression of agnoprotein in trans restores the
replication activity of the JCV Pt mutant virus
Having established the functional significance of agnopro-
tein in viral replication, we asked whether the stable
expression of agnoprotein in trans can complement the
loss of agnoprotein expression from the viral background
and restore the replication activity of Pt mutant to that of
the WT levels. To address this question, SVG-A cells were
stably transfected with an agnoprotein expression plasmid
and stable clones expressing JCV agnoprotein were
selected. An agnoprotein positive clone was then trans-
fected either with JCV Mad-1 WT or Pt mutant viral gen-
ome and replicated DNA analyzed by Southern blotting.
In parallel, an SVG-A control clone which was stably
transfected with an empty vector was also transfected
either with WT genome or Pt mutant genome. As shown
in Figure 6A, a clear difference of about 11.6-fold was
observed between the replication efficiency of WT and
JCV Mad-1 
        WT
JCV Mad-1 
    Pt Mut
AGNO Merge DAPI VP1
Figure 3 Immunocytochemical analysis of SVG-A cells transfected/infected either with JCV Mad-1 WT or its Pt mutant genome for
detection of agnoprotein (AGNO) and VP1 expression. SVG-A cells were transfected either with JCV Mad-1 WT or the Pt mutant genome, fixed
at 6
th day posttranfection, incubated with a primary anti-Agno polyclonal and anti-VP1 (PAb597) monoclonal antibodies followed by incubation with a
FITC-conjugated goat anti-rabbit and Rhodamine-conjugated goat anti-mouse secondary antibodies and examined under a fluorescence microscope
for detection of JCV agnoprotein and VP1 expression. DAPI staining was also performed to visualize the nucleus of the cells.
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Page 7 of 15that of the Pt mutant genomes at day 21 in the control
cells (compare lane 4 to 5). However, the difference
between the replication efficiency of WT and that of the
Pt was much lower (about 1.6-fold) when the viral gen-
omes were separately transfected into an agnoprotein-
expressing clone (compare lane 8 to 9). These data indi-
cate that stable expression of agnoprotein in trans restores
the replication activity of the mutant genome. It should be
noted here however that there appears to be variation
between the data points between the control and the
complementation group. For instance, when compared the
replication efficiency of the control lanes at 14
th day post-
transfection with that of the complementation group in
this figure, the latter is lower. This is most likely due to
the clonal variation as well as the growth differences
between the cells, since one clone is constitutively expres-
sing agnoprotein and the other is not. We have found pre-
viously that agnoprotein markedly inhibits cell growth
[16]. (This may account for this variation with respect to
the level of replication of either JCV WT or the Pt mutant
A
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41
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Pt
Pt
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1d 9d 6d 3d
66
41
16 5 4 3 2 79 8
66 Lamin A/C
Lamin A/C
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Figure 4 Analysis of late capsid protein (VP1) expression in PHFG cells transfected/infected with either JCV Mad-1 WT or its Pt mutant
genome. (A) Nuclear extracts were prepared from PHFG cells transfected either with JCV Mad-1 WT or Pt mutant genome and analyzed by
Western blot for VP1 expression. (B) CV-1 cells were transfected either with SV40(776) WT or the Pt mutant genome; and the nuclear extracts
were prepared at the days indicated and analyzed by Western blot for VP1 expression. In lane 1 in each panel, nuclear extracts prepared from
untransfected cells were loaded as negative control (- Cont.). Blots for panel A and B were also analyzed for Lamin A and C expression to
demonstrate equal loading of nuclear proteins onto the gels.
Sariyer et al. Virology Journal 2011, 8:255
http://www.virologyj.com/content/8/1/255
Page 8 of 1516 5 4 3 2 7
Replicated
DNA
Input DNA
Pt
WT
Pt
WT
Pt
WT
+ Cont.
16 5 4 3 2 7
Replicated
DNA
Input DNA
Pt
WT
Pt
WT
Pt
WT
+ Cont.
14d 7d Time Points: 21d
A JCV
6d 3d 9d
B
Time Points:
SV40
Figure 5 Replication efficiency of JCV and SV40 Pt mutants. (A) SVG-A cells were transfected with either JCV Mad-1 WT or the Pt mutant
genome. Low molecular-weight DNA was isolated at the time points indicated, digested with BamH I and Dpn I enzymes, resolved on a 0.8%
agarose gel, and analyzed by Southern blotting. In lane 1, JCV Mad-1 WT genome (2 ng) digested with BamH I was loaded as a positive control
(+ Cont.). (B) CV-1 cells were transfected with either SV40(776) WT or its Pt mutant genome and the replication efficiency of both genomes was
assessed by Southern blotting as described for panel A. Replication studies with WT and the Pt mutants for both JCV and SV40 genomes were
repeated more than three times and a representative data is shown here. The input DNA (transfected), which is digested by Dpn I is indicated
by the brackets. In lane 1, SV40(776) genome (2 ng) digested with BamH I was loaded as a positive control (+ Cont.).
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Figure 6 Analysis of the replication efficiency of JCV WT and its Pt mutant in agnoprotein positive cells.( A )S V G - Ac e l l sw e r es t a b l y
transfected with an agnoprotein expression plasmid and clones selected as described in Materials and Methods. Cells expressing agnoprotein or
the control cells (stably transfected with empty vector) were transfected with either JCV Mad-1 WT or its Pt mutant genome as indicated. Low
molecular weight DNA was isolated and analyzed by Dpn I-Southern blot analysis as described in Figure. 5A. In lane 1, JCV Mad-1 WT genome
(2 ng) digested with BamH I was loaded as a positive control (+ Cont.). (B) Western blot analysis of the stable expression of agnoprotein in
SVG-A cells. In lane 1, whole cell extracts prepared from the SVG-A cells stably transfected with empty vector were loaded as negative control
(- Cont.). In lane 2, whole cell extract prepared from an agnoprotein positive clone was loaded.
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Page 9 of 15in control group (Agno-negative) at 14d posttransfection
compared to those in the complementation group (Agno-
positive) for the same day. However, the most important
point in this figure is that the gap between the levels of
replication of WT versus the Pt mutant gets wider as the
replication cycle proceeds for the control group, where no
agnoprotein was produced by the cells. For instance, while
there is an approximately 12-fold difference between WT
and the Pt mutant at 21d posttransfection (lanes 4 and 5),
this difference decreased to~ 1 . 6f o l df o rt h es a m ed a y
data point in the complementation group (lanes 8 and 9),
suggesting that providing agnoprotein in trans comple-
ments its loss during the replication cycle of JCV. Figure
6B demonstrates the expression level of agnoprotein in
clone #9 by Western blotting.
Analysis of the virions released from SVG-A cells
transfected/infected with JCV Pt mutant
So far, our results showed that the propagation of JCV
was significantly hampered in the absence of agnoprotein.
We next wanted to address the following questions: (i) is
this due to possible defects occurring in the release of
the virions from the infected cells or (ii) is some other
mechanism involved such as the release of defective vir-
ions during the course of viral infection? To address
t h e s ep o s s i b i l i t i e s ,w ee m p l o y e dav i r i o nr e l e a s ea s s a y ,
where the released virions present in the supernatant of
the transfected cells were immunoprecipitated with anti-
body raised against the capsid protein VP1 and samples
were divided into two equal portions, one portion of
which was analyzed by Western blotting (Figure 7B) and
the other portion was analyzed by Southern blotting
(Figure 7B). Western blot analysis of the released capsid
proteins (VP1) for both WT and Pt mutant showed that
virions were efficiently released from infected cells and
were readily detectable at 35d posttransfection for both
WT and the Pt mutant. However, analysis of the genomic
content of the released virions by Southern blotting sur-
prisingly showed that the virions released from the cells
transfected with Pt mutant infected cells were mostly
devoid of viral DNA compared to WT (Figure 7B). These
findings suggest that viral virions are efficiently released
from the infected cells in the absence of agnoprotein, and
yet they are deficient with respect to the genomic con-
tent, which may account for, at least in part, why the Pt
mutant virus is defective in viral propagation. The lack of
detection of viral genome in released virions may be
attributed to the possible defects in virion biogenesis
and/or viral DNA replication processes of Pt mutant.
Analysis of the virions released from CV-1 cells
transfected/infected with SV40 Pt mutant
In parallel, we also performed a virion release analysis
for SV40. CV-1 cells were either transfected/infected
with SV40(776) WT or its Pt mutant genome and
supernatants from transfected/infected cells were col-
lected at different time points as indicated and subjected
to immunoprecipitation with anti-VP1 antibody. The
immunoprecipitated samples were divided into two
equal half portions. One half was analyzed for detection
of viral capsid protein VP1 by Western blot and the
other half was analyzed by Southern blotting to evaluate
the level of viral DNA encapsidated into the released
virions. As shown in Figure 8A, similar to JCV, the
SV40 viral particles were efficiently released from the
infected cells in the absence of agnoprotein, which was
evident from the significant level of detection of VP1 for
Pt mutant compared to WT (Figure 8A). However the
DNA content of the released virions for Pt mutant
was almost undetectable while the DNA content of
WT DNA was much higher than that of the Pt mutant
(Figure 8B, compare lanes 2-4 to 5-7). As for JCV, this
may, at least in part, explain why SV40 agnoprotein Pt
mutant cannot efficiently propagate compared to WT.
Of note, there appears to be differences when compared
the data for the WT and the Pt VP1 samples in Figure 8
with those obtained for Figure 4B. This apparent discre-
pancy can be explained as follows. These two experi-
mental settings are different. In Figure 4B, the level of
expression of VP1 was analyzed using extracts prepared
from infected cells at the indicated data points. How-
ever, in Figure 8A, VP1 levels were determined in
immunoprecipitated virions that are released into and
accumulated in the culture media from the day of trans-
fection on and up to the day of data collection. Due to
this difference in experimental settings, variations in
results are expected. However, overall, the virion release
assays have demonstrated that both JCV and SV40
agnoprotein Pt mutants behave similarly with respect to
the efficiency of the release of the virions from the
infected cells and the deficiency of DNA content in
released viral particles.
Analysis of growth properties of SV40 Pt mutant in Cos-7
cells, constitutively expressing SV40 large T antigen
The main regulatory protein of human (JCV and BKV)
and primate (SV40) polyomaviruses is the LT-Ag, which
is responsible for initiation of the viral DNA replication
and transactivation of the viral late genes. We have
demonstrated in this work that, in the absence of agno-
protein, these viruses are unable to replicate as efficiently
as WT. Our data from replication assays in SVG-A cells
(Figure 5A) showed that providing LT-Ag to the replica-
tion system in vivo, in the absence of agnoprotein, is not
sufficient to alleviate the replication level of JCV Mad-1
Pt mutant closer to that of JCV Mad-1 WT. Of note,
SVG-A cells constitutively express SV40 LT-Ag [40]. In
order to address the same question for SV40 Pt mutant,
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Figure 8 Analysis of the virions released from CV-1 cells transfected/infected with either SV40(776) WT or its Pt mutant. CV-1 cells were
transfected with either SV40(776) WT or Pt mutant genome and supernatants from infected cells were collected at time points indicated for
analysis of the released virions by Western blot for VP1 (A) and Southern blotting (B) as described for the figure legends for Figure. 7A. and
Figure. 8B respectively. In lane 1 in panel A, supernatant from uninfected cells was immunoprecipitated with anti-VP1 antibody and loaded as a
negative control (- Cont.). In lane 1 in panel B, SV40(776) genome (2 ng) digested with BamH I was loaded as a positive control (+ Cont.).
WT
Pt Replicated
DNA
Time 
Points: 21d
35d
+ Cont.
- Cont.
14 3 2
Pt
WT
14 3 2
Time 
Points: 21d
35d
+ Cont.
- Cont.
VP1
Released JCV virions 
   in culture media
 Released virions analyzed by 
     IP/Western blotting
    Genomic content of the released 
virions analyzed by IP/Southern blotting
Replicated
DNA
A B
VP1
Figure 7 Analysis of the virions released from PHFG cells transfected/infected with either JCV Mad-1 WT or its Pt mutant. Supernatants
from the transfected/infected PHFG cells were collected at indicated time points centrifuged at 16,000 × g to clear the cell debris and were
subjected to immunoprecipitation using an anti-VP1 antibody (PAb597) to precipitate the released virions. Immunoprecipitants were divided into
two equal portions, one of which was analyzed by Western blotting to detect viral capsid protein VP1 (A) and the other was analyzed by
Southern blotting for the detection of the encapsidated viral DNA (B). In lane 1 in panel A, supernatant from infected cells was
immunoprecipitated with anti-VP1 antibody and loaded as a positive control (+ Cont.). In lane 2 in panel A, supernatant from uninfected cells
was immunoprecipitated with anti-VP1 antibody and loaded as a negative control (- Cont.). In lane 1 in panel B, JCV Mad-1 genome (2 ng)
digested with BamH I was loaded as a positive control (+ Cont.). In lane 2 in panel B, supernatant from uninfected cells was
immunoprecipitated, digested with BamH I and loaded as a negative (- Cont.).
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Page 11 of 15that is whether constitutive expression of SV40 LT-Ag is
sufficient to bring the replication level of SV40 Pt mutant
closer to that of SV40 WT, Cos-7 cells which constitu-
tively express SV40 LT-Ag, were transfected with either
SV40 (776) WT or its Pt mutant as described in the
legend for Figure 9, and the efficiency of infection was
examined by both immunocytochemistry (Figure 9A) and
Western blotting (Figure 9B). Overall immunocytochem-
istry studies showed that majority of the cells were
labeled with anti-agno antibody (green) and anti-VP1
antibody (red) VP1, as expected, when cells were trans-
fected/infected with SV40 WT (Figure 9A). However, a
few of the cells (1-5%) were labeled when the cells were
transfected/infected with SV40 Pt mutant (Figure 9A
lower panels). In parallel studies, comparison of VP1
expression of WT with that of Pt mutant by Western
blot analysis was found to be correlated with those from
immunocytochemistry studies respectively (Figure 9B).
WT
Time Points:
1d
6d
3d
1d
6d
3d
41
26
VP1
16 5 4 3 2 7
Pt B
A
SV40 
WT
SV40 
Pt Mut
AGNO DAPI VP1 Merge
- Cont.
Figure 9 Analysis of the growth rate of SV40 Pt mutant in Cos-7 cells by immunocytochemistry and Western blotting. (A) Cos-7 cells
were transfected/infected with either SV40(776) WT or its Pt mutant as described in materials and methods and at 6
th day posttransfection, cells
were fixed in cold acetone, washed with 1 × PBS and incubated with both anti-agno polyclonal rabbit [19] and anti-VP1 (PAb597) monoclonal
mouse primary antibodies (1:200 dilution each). After washing the primary antibodies with 1 × PBS, cells were incubated with secondary
antibodies, goat anti-rabbit FITC-conjugated (green), and goat anti-mouse Rhodamine-conjugated (red) antibodies. Cells were finally washed with
1 × PBS, mounted in mounting media containing DAPI stain (Vector laboratories Inc. CA) and examined under fluorescent microscope. (B)
Western blot analysis of nuclear extracts for VP1 expression, prepared from Cos-7 cells transfected/infected with either SV40 (776) WT or its Pt
mutant as described for panel A above. Nuclear extracts (10 μg/each sample) were resolved on a 10% SDS-PAGE, transferred onto a
nitrocellulose membrane and probed with anti-VP1 monoclonal antibody (PAb597). In lane 1, nuclear extracts from untransfected Cos-7 cells
were loaded as a negative control (- Cont.).
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Page 12 of 15Taken together, as it was observed for JCV Pt mutant
replication in SVG-A cells (Figure 5A), the constitutive
expression of SV40 LT-Ag in Cos-7 cells is not sufficient
to alleviate the Pt replication level to that of SV40 WT.
In other words, agnoprotein is required for the efficient
replication of both JCV and SV40.
Discussion
The regulatory roles of agnoprotein in JCV life cycle are
not fully understood. In this work, we specifically inves-
tigated the regulatory role(s) of JCV and SV40 agnopro-
tein in virion release utilizing agnoprotein point mutants
of each virus in which the ATG initiation codon has
been removed so as to ablate expression. We found that
both JCV and SV40 viral gene expression and replica-
tion were drastically reduced in the absence of agnopro-
tein suggesting that both viruses require agnoprotein for
the successful completion of their lytic cycle. Our find-
ings are also supported by a recent report by Myhre
et al, in which it was demonstrated that a non-func-
tional BKV mutant with deletions in the agnogene
can be complemented in trans from a co-existing BKV
rr-NCCR variant [38].
In addition, consistent with our findings from gene
regulation studies, JCV and SV40 agnoprotein Pt
mutants showed an enormous negative effect on viral
DNA replication. SVG-A cells used in replication assays
were derived from PHFG cells by stably transfecting a
replication defective SV40 genome [40]. This cell line
expresses the viral early regulatory protein, LT-Ag, but
not the viral late genes including agnoprotein. Prepara-
tion of PHFG cells is labor intensive, costly, and there is
variability between the batches of cell preparations,
greatly affecting consistency of the results. SVG-A cells
constitutively express SV40 LT-Ag, which was pre-
viously shown to cross-regulate JCV replication [45-48],
but our data presented in this work convincingly
showed that expression of SV40 LT-Ag alone is not suf-
ficient for the efficient replication of neither JCV Pt
mutant in SVG-A cells (Figure 5A) nor SV40 Pt mutant
in Cos-7 cells (Figure 9), which also constitutively
express SV40 LT-Ag. It should be noted here that the
origin of DNA replication of JCV and SV40 in agnopro-
tein Pt mutants was intact, which was verified by
sequencing. As such, the relatively low level of replica-
tion of JCV and SV40 Pt mutants compared to their
WTs cannot be attributed to the unintended mutations
that occurred during the mutagenesis process, which
greatly affect the replication of each mutant. Therefore,
it was expected that SV40 LT-Ag would up-regulate
JCV replication in agnoprotein Pt mutant background
regardless of the absence of agnoprotein. However, we
found that agnoprotein is required for efficient regula-
tion of JCV and SV40 replication in the context of the
w h o l ev i r a lg e n o m e ,i . e . ,t h ec o n s t i t u t i v ee x p r e s s i o no f
SV40 LT-Ag is not sufficient to complement the
absence of agnoprotein for the efficient replication of
JCV and SV40. In fact, the results from the complemen-
tation assays support this conclusion and demonstrate
that the level of replication of the JCV agnoprotein Pt
mutant is alleviated to a level comparable to that of WT
when agnoprotein is provided to the replication system
in trans (Figure 6A).
We also investigated the question of whether agnopro-
tein has a role in the release of viral particles and found
that JCV and SV40 virions are efficiently released from
the infected cell in the absence agnoprotein, but they
a r em o s t l yd e f i c i e n ti nv i r a lD N Ac o n t e n t( F i g u r e7 B
and 8B). Our findings are in contrast with the recent
report by Suzuki et al. [39] which suggests that agnopro-
tein functions as a viroporin and therefore may play a
role in release of virions from JCV-infected cells. Our
results do not support this idea since we found that
viral particles were efficiently released from infected
cells to the culture medium in the absence of agnopro-
tein. However, the released virions are not as infectious
particles as those of WT due to the lack of viral encap-
sidated DNA, i.e., they appear to be mostly composed of
empty capsids and therefore unable to initiate an effi-
cient next round of the infection cycle. This may be the
major reason why the level of propagation of agnopro-
tein Pt mutant is profoundly reduced compared to that
of WT.
Conclusions
The small regulatory proteins of many viruses play
important roles in regulation of the viral life cycle and
are therefore critical to the fine tuning of many aspects
of virus-host interactions. Our findings in this report
indicate that the agnoprotein of JCV and SV40 is
required for efficient regulation of viral DNA replication
and gene regulation. This may have functional conse-
quences for the successful completion of the JCV lytic
cycle. In light of our findings, we propose that agnopro-
tein may substantially contribute to the process of pro-
portional production of viral capsid proteins versus that
of viral DNA, thereby leading to the formation of a high
number of optimally infectious viral particles for the next
round of the infection cycle. Finally, given the fact that
JCV is the etiologic agent of PML and may be involved in
the induction of some of the human malignancies, such
findings make agnoprotein an attractive target for thera-
peutic approaches to control JCV-induced diseases in the
affected individuals. Understanding the molecular
mechanisms associated with the regulatory functions of
agnoprotein is important for unraveling the molecular
secrets of the unique biology of JCV and JCV-associated
diseases.
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